Bone health and osteoporosis screening in gynecologic cancer survivors

Gynecol Oncol. 2021 Feb;160(2):619-624. doi: 10.1016/j.ygyno.2020.11.028. Epub 2020 Dec 11.

Abstract

Cancer treatment-induced bone loss is a known side effect of cancer therapy that increases the risk of osteoporosis and bone fracture. Women with gynecologic cancer are at increased risk of bone loss secondary to the combined effect of oophorectomy and adjuvant therapies. Data regarding bone loss in women with gynecologic cancers are overall lacking compared to other cancer populations. Consequently, guidelines for osteoporosis screening in women with cancer are largely based on data generated among non-gynecologic cancer survivors. This article reviews current available data of bone health in women with gynecologic cancer, summarizes best-available guidelines for screening for osteoporosis in women with cancer, and provides guidance for osteoporosis screening in women with gynecologic cancers based on best available evidence.

Publication types

  • Review

MeSH terms

  • Absorptiometry, Photon
  • Antineoplastic Agents, Hormonal / adverse effects
  • Bone Density / drug effects
  • Bone Density / physiology*
  • Bone Density / radiation effects
  • Cancer Survivors / statistics & numerical data*
  • Chemotherapy, Adjuvant / adverse effects
  • Chemotherapy, Adjuvant / methods
  • Evidence-Based Medicine / standards
  • Female
  • Genital Neoplasms, Female / complications
  • Genital Neoplasms, Female / mortality
  • Genital Neoplasms, Female / therapy*
  • Humans
  • Mass Screening / standards*
  • Menopause / drug effects
  • Menopause / metabolism
  • Menopause / radiation effects
  • Osteoporosis / diagnosis*
  • Osteoporosis / epidemiology
  • Osteoporosis / etiology
  • Osteoporosis / metabolism
  • Ovary / drug effects
  • Ovary / metabolism
  • Ovary / radiation effects
  • Ovary / surgery
  • Practice Guidelines as Topic
  • Radiotherapy, Adjuvant / adverse effects
  • Risk Factors
  • Salpingo-oophorectomy / adverse effects
  • Survivorship

Substances

  • Antineoplastic Agents, Hormonal